-->Skip to main content
Request an appoinment Download results

Women's Health

We offer a wide range of analytical tests that enables us to provide gynaecologists with a comprehensive and personalised diagnostic service for women, with special emphasis on prenatal diagnosis and diagnosis of women’s cancers and/or diseases of infectious origin.

SYNLAB was a pioneer in introducing non-invasive prenatal genetic testing in Europe, also being the first laboratory in the world to apply bidirectional paired-end sequencing (WGS) technology in this type of genetic study.

Advanced technology

We are committed to new technologies applied to molecular biology and genetics, continuously investing in the most advanced platforms for massive DNA sequencing which have revolutionized the concept of prevention and personalized patient treatment.

Analytical control aimed at assessing the possible adverse effects of taking oral contraceptives in patients with risk factors.



    Anatomopathological analysis of conventional cytology samples, liquid cytology and FNA.

  • PAPILLOMAVIRUS (detection and typing)

    Detection of human papillomavirus (HPV) and typing of 14 genotypes associated with high oncogenic risk (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and two low-risk genotypes (HPV 6 and 11).

Screening for sexually transmitted infections is carried out using bacteriological, serological and molecular techniques based on the microorganism to be studied.

Determination of the anti-Müllerian hormone makes it possible to indirectly evaluate the quantity and quality of a woman’s reserve of oocytes, as well as to predict the onset of menopause or confirm the suspicion of PCOS, before indicating some assisted reproduction techniques.

preconGEN is a study of carriers of X-linked recessive or monogenic diseases in couples, recipients or donors through NGS sequencing. 

We use the most advanced and accurate techniques for detecting the hormones involved in the functioning of the thyroid or the hypothalamic-pituitary-adrenal/gonadal axis, including high performance liquid chromatography (HPLC) and RIA immunoassays.

We use the most advanced systems of analysis to perform semenograms, such as the SCA CASA system, thereby ensuring reliable, linear and accurate results.

In the case of infertility, prior genetic studies of the couple or foetus have helped us to understand and reorient the treatment of couples with problems.

This makes it possible to detect numerical and structural anomalies in an individual’s chromosomal endowment.

  • Detection and analysis of copy number variations, gains and losses, with a resolution 100 times higher than constitutional karyotyping.
  • Exon-level coverage of more than 354 genes associated with developmental disorders identified in the DDD and ClinGen projects.
  • Lower failure rate and shorter turnaround time; no need for cell culture prior to assay.

This makes it possible to detect numerical and structural anomalies in an individual’s chromosomal endowment.

    Study of acquired or hereditary thrombophilias by means of biochemical analysis or detection of genetic mutations associated with recurrent miscarriages and with the development of venous thromboembolism.
    Determination of the concentration of the free beta subunit of chorionic gonadotropin (fβ hCG) and of the plasma protein A (PAPP-A) associated with pregnancy.
  • GMDpredict
    Genetic test for predisposition to gestational diabetes mellitus (GDM)
  • Foetal Sex Determination
    Molecular detection of the SRY gene through analysis of cell-free foetal DNA present in maternal blood.
  • neoBona
    Non-invasive prenatal screening for the most common aneuploidies (chromosomes 13, 18 and 21).
    Screening test to determine the risk of preeclampsia (PE) in the first trimester.

    Analysis of cell-free foetal DNA in maternal blood for the detection of specific exons of the RhD gene by means of quantitative real-time PCR.
    Determination of the concentration of alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG) and inhibin A, markers present in the mother’s blood that come from the foetus and placenta..
    This is a diagnostic test for gestational diabetes that is performed around the 24th and 28th week of gestation.
    Diagnostic analysis to determine the risk of PE in the second or third trimester.
    From the 19th week of gestation, we can use molecular techniques to detect the main infections transmissible from mother to foetus: toxoplasmosis, rubella, chickenpox, and parvovirus, etc.

    Detection of Streptococcus agalactiae in vaginal and faecal samples to assess the administration of intrapartum antibiotic prophylaxis.

myNewbornDNA - Screening for actionable, early-onset, genetic diseases. This test analyses 407 genes associated with the development of metabolic, endocrine, autoimmune, neurological and deafness-related illnesses, and other pathologies, such as cystic fibrosis or biotinidase deficiency, through whole exome sequencing.

We offer the most advanced and accurate techniques for the detection of hormones that undergo alteration during menopause.

Determination of biochemical markers of bone remodelling to identify patients with a high risk of fracture, and to monitor therapeutic responses.

    Hereditary predisposition to breast, ovarian and endometrial cancer.
    Hereditary predisposition to breast, ovarian and endometrial cancer.

Gene signatures for breast cancer prognosis and management.

    Detection of antigens in tissue samples for diagnosis and typing of diseases such as cancer, which, in turn, make it possible to assess the presence of predictive factors for therapeutic response (Her2/neu, PDL1, ER and PR among others).

More advanced molecular pathology techniques for the diagnosis of both breast and ovarian tumours (example: BRCA1 and BRCA2 in tissue to determine whether or not to use Olaparib in cancer patients).

SYNLAB online genetic counselling

ONMEDICALL is an online genetic counselling platform through which the specialist can receive genetic counselling from SYNLAB experts via videoconferencing at no additional cost. 

360º Service 
automation and traceability

  • 01
    Sample collection

    organized by our Logistics Department with the necessary frequency for each customer

  • 02
    Sample processing

     within the time frame indicated

  • 03
    Issuance of the report

     in the most appropriate format for each customer (paper, electronic or via access to our platform)

  • 04
    Online genetic counselling


Solicita Información


Nota informativa sobre el ciberataque acontecido en Synlab ITALIA

El pasado 18 de Abril Synlab Italia se vio afectada por las consecuencias de un ciberataque. Como precaución y, de acuerdo con los procedimientos de seguridad de la información de Synlab, todos los sistemas en Italia fueron desactivados. Como resultado, las operaciones de Synlab en Italia se vieron suspendidas. Se estableció un equipo de trabajo con expertos internos y externos para mitigar el impacto, restaurar los sistemas y se alertó a las autoridades con quien se ha colaborado estrechamente.

Las operaciones fuera de Italia NO se vieron afectadas por este incidente.

Con fecha 30 de abril Synlab Italia ha restaurado sus operaciones y retomará los servicios a pacientes y clientes en Italia.

Synlab está comprometida en mantener los más altos estándares de seguridad e integridad.